Cantor Fitzgerald Downgrades RAPT Therapeutics to Neutral
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Prakhar Agrawal downgraded RAPT Therapeutics (NASDAQ:RAPT) from Overweight to Neutral, indicating a shift in the firm's outlook on the company.

February 20, 2024 | 7:14 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cantor Fitzgerald downgraded RAPT Therapeutics from Overweight to Neutral, suggesting a more cautious view on the company's stock.
Analyst downgrades typically lead to a negative short-term impact on the stock price as they reflect a less optimistic view on the company's future performance. Given the downgrade is from Overweight to Neutral, it suggests a significant change in the analyst's outlook, potentially leading to decreased investor confidence and a drop in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100